Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People Wit
A phase 1/2 trial of Zongertinib, Trastuzumab deruxtecan, Trastuzumab emtansine in colorectal cancer, run by Boehringer Ingelheim, now recruiting.
Overview
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread is a phase 1/2 interventional study registered as NCT06324357 by Boehringer Ingelheim, with 768 participants planned, started 2024-06-28 and due to reach its primary completion in 2029-01-08. Interventions recorded: Zongertinib, Trastuzumab deruxtecan, Trastuzumab emtansine, Trastuzumab, Capecitabine. Conditions listed: Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialBeamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations
Shares Zongertinib, Boehringer Ingelheim.
- TrialBeamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
Shares Zongertinib, Boehringer Ingelheim.
- TrialBeamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab
Shares Zongertinib, Boehringer Ingelheim.
- TrialBeamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutati
Shares Zongertinib, Boehringer Ingelheim.
- TrialMOUNTAINEER & MOUNTAINEER-03
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Trastuzumab, Colorectal cancer.
- TrialA Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
Shares Capecitabine, Trastuzumab, Trastuzumab deruxtecan.
- TrialPh1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
Shares Capecitabine, Trastuzumab, Trastuzumab deruxtecan.
- TrialA Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorectal Cancer
Shares Capecitabine, Colorectal cancer.